Mercer Global Advisors’s Denali Therapeutics DNLI Stock Holding History

Mercer Global Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$418K	Buy	+16,257	New	+$334K	﹤0.01%	2466
2023 Q2	–	Sell	-26,299	Closed	-$606K	–	1951
2023 Q1	$606K	Sell	26,299 -731	-3%	-$20.1K	﹤0.01%	1108
2022 Q4	$752K	Buy	27,030 +821	+3%	+$24.4K	﹤0.01%	1031
2022 Q3	$804K	Buy	26,209 +2,346	+10%	+$76.3K	﹤0.01%	936
2022 Q2	$702K	Buy	23,863 +948	+4%	+$24.8K	﹤0.01%	990
2022 Q1	$737K	Buy	22,915 +5,563	+32%	+$191K	﹤0.01%	1037
2021 Q4	$774K	Sell	17,352 -2,181	-11%	-$103K	﹤0.01%	1000
2021 Q3	$985K	Buy	+19,533	New	+$1.1M	0.01%	867

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mercer Global Advisors's DNLI Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 16,257 shares worth $418K. The stake represents ﹤0.01% of the portfolio and ranks #2466 among its holdings. This is a return to the name: Mercer Global Advisors previously reported a position in DNLI as recently as Q1 2023.

Mercer Global Advisors first reported a position in DNLI in Q3 2021 and has held it in 8 quarters since. The position peaked at $985K in Q3 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Mercer Global Advisors held 16,257 shares of Denali Therapeutics worth $418K as of Q2 2026.
Denali Therapeutics was a new Mercer Global Advisors position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2466 holding.
Mercer Global Advisors first reported a position in Denali Therapeutics in Q3 2021 and has held it in 8 quarters since.
Mercer Global Advisors's Denali Therapeutics position peaked at $985K in Q3 2021.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.